Sharing Life Sciences Innovations

Join our 20.000 subscribers and receive the newsletter for free!

Upcoming events

International Francqui Chair: Curing hemophilia: from Royal disease to gene therapy

Auditorium 1.008, building S2, Campus Sterre, Krijgslaan 281, 9000 Ghent
Wed 01 Mar 2017
16:00

Professor VandenDriessche is tenured Professor at the Faculty of Medicine and Pharmacy and Director of the Department of Gene Therapy and Regenerative Medicine of the Free University of Brussels (…

Read more

International Francqui Chair: Gene therapy flexes its muscles: new prospects for treating hereditary muscular diseases

Auditorium 1.008, building S2, Campus Sterre, Krijgslaan 281, 9000 Ghent
Wed 08 Mar 2017
16:00

Professor VandenDriessche is tenured Professor at the Faculty of Medicine and Pharmacy and Director of the Department of Gene Therapy and Regenerative Medicine of the Free University of Brussels (…

Read more

FlandersBio-Janssen Pharmaceutica Partner Day 2017

University of Antwerp, Campus Drie Eiken - Building O, Universiteitsplein 1, 2610 Wilrijk
Thu 09 Mar 2017
09:30

The annual FlandersBio-Janssen Pharmaceutica Partner Day “Together towards a Flemish Healthcare cluster: Example collaborations and best practices in CNS" will take place on March 9th, 2017 in Ant…

Read more

V-Bio feature: Mosquito Wars

V-Bio feature: Mosquito Wars

Mosquitoes are carriers of a range of crippling diseases, posing an enormous global health burden. Because current methods based on insecticides are inadequate, new tools are urgently needed. Wide…

Read more

Combination therapy for cystic fibrosis tested in clinical trial

Mechelen, Belgium; 23 February 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GL…

Read more

Apitope announces positive phase IIa data in relapsing Multiple Sclerosis

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead produc…

Read more

Four times more funds for VIB

The Flemish Government will increase the annual support for the VIB from 15 million to 59 million per year. "The VIB is the catalyst of the Flemish biotechnology sector. It's an excellent referenc…

Read more

Interspecies chimeras: One embryo, two species

Interspecies chimeras: One embryo, two species

The creation of an interspecies embryo in the lab sends tremors through the scientific world and beyond. This pig embryo containing human cells presents many exciting possibilities, such as creati…

Read more

PharmaFluidics Micro-Chips: Not for Computers

PharmaFluidics Micro-Chips: Not for Computers

The boundaries of technology can be pushed significantly when insights from different fields reinforce each other. A prime example is VUB spin-off PharmaFluidics. By combining expertise from the b…

Read more

Alzheimer's, ALS or a brain injury: ADx neurosciences knows how to tackle it

Alzheimer's, ALS or a brain injury: ADx neurosciences knows how to tackle it

ADx NeuroSciences might be described best as the Intel of biomarker assays for neuro-degenerative disease. They don’t create complete kits, but their top-notch biomaterials are included in the ass…

Read more

USING BACTERIA TO FIGHT OBESITY AND DIABETES

USING BACTERIA TO FIGHT OBESITY AND DIABETES

Using the gut bacterium Akkermansia muciniphila to treat obese and diabetic patients is now one step closer to becoming a reality, thanks to the work of a group of researchers led by Patrice Cani …

Read more

Connecting science and citizens

Connecting science and citizens

The ways people are conducting bioscience are changing. Cheaper equipment has paved the way for citizens to perform increasingly advanced experiments. So-called citizen scientists have recently be…

Read more

V-Bio Ventures spends big money in life sciences

V-Bio Ventures spends big money in life sciences

Only one year after its inception, the life science investment fund V-Bio Ventures made its first investments in three companies and announced the final closing of their first fund. Time to discus…

Read more

Confo Therapeutics: Drugging the Undruggable

Confo Therapeutics: Drugging the Undruggable

Llama single-domain antibodies have found yet another application, one that Confo Therapeutics is fully exploiting. Ablynx is developing Nanobodies®, AgroSavfe focuses on Agrobodies®, and Confo wi…

Read more

Join our 20.000 subscribers and receive the newsletter for free!

Upcoming events

International Francqui Chair: Curing hemophilia: from Royal disease to gene therapy

Auditorium 1.008, building S2, Campus Sterre, Krijgslaan 281, 9000 Ghent
Wed 01 Mar 2017
16:00

Professor VandenDriessche is tenured Professor at the Faculty of Medicine and Pharmacy and Director of the Department of Gene Therapy and Regenerative Medicine of the Free University of Brussels (…

Read more

International Francqui Chair: Gene therapy flexes its muscles: new prospects for treating hereditary muscular diseases

Auditorium 1.008, building S2, Campus Sterre, Krijgslaan 281, 9000 Ghent
Wed 08 Mar 2017
16:00

Professor VandenDriessche is tenured Professor at the Faculty of Medicine and Pharmacy and Director of the Department of Gene Therapy and Regenerative Medicine of the Free University of Brussels (…

Read more

FlandersBio-Janssen Pharmaceutica Partner Day 2017

University of Antwerp, Campus Drie Eiken - Building O, Universiteitsplein 1, 2610 Wilrijk
Thu 09 Mar 2017
09:30

The annual FlandersBio-Janssen Pharmaceutica Partner Day “Together towards a Flemish Healthcare cluster: Example collaborations and best practices in CNS" will take place on March 9th, 2017 in Ant…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

FlandersBio Bridge 2 Health Biowin NLO KU Leuven Lifetech.brussels UGent VIB Janssen Turnstone Itera Life Science V-Bio Ventures GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.